Business
HLS Therapeutics Announces that Amarin's REDUCE-IT(TM) Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint
HLS Therapeutics Announces that Amarin's REDUCE-IT™ Cardiovascular Outcomes Study o...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics Announces that Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Sept. 24, 2018\n\n\n\nREDUCE-IT is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific to Pure EPA Vascepa at 4 Grams Daily HLS has the Rights to Vascepa for the Canadian Market Amarin to Host Conference Call Scheduled for Today, Monday September 24, 2018 at 8:00 am ET TORONTO, Sept. 24, 2018 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX-V:HLS) announces that earlier today, Amarin Corporation plc (NASDAQ:AMRN), issued topline results from the Vascepa® cardiovascular (\"CV\") outcomes trial, REDUCE-IT™, a global study of 8,179 statin-treated adults with elevated CV risk. REDUCE-IT met its primary endpoint demonstrating an approximately 25% relative risk reduction, to a high degree of statistical significance (p<0.001), in major adverse CV events (\"MACE\") in the intent-to-treat patient population with use of Vascepa 4 grams/day as compared to placebo. HLS has in-licensed the rights to Vascepa for the Canadian market.\nPatients enrolled in REDUCE-IT had LDL-C between 41-100 mg/dL (median baseline LDL-C 75 mg/dL) controlled by statin therapy and various CV risk factors including persistent elevated triglycerides (\"TGs\") between 150-499 mg/dL (median baseline 216 mg/dL) and either established CV disease (secondary prevention cohort) or diabetes mellitus and at least one other CV risk factor (primary prevention cohort).\nKey topline results include:\nEfficacy: Approximately 25% relative risk reduction, demonstrated to a high degree of statistical significance (p<0.001), in the primary endpoint composite of the first occurrence of MACE, including CV death, nonfatal myocardial infarction (\"MI\"), nonfatal stroke, coronary revascularization, or unstable angina requiring hospita...